Tumor Necrosis Factor Blocker [EPC]

978548 reported adverse events

Drugs of this class: ADALIMUMAB-BWWD ADALIMUMAB-ADAZ ADALIMUMAB-ATTO INFLIXIMAB ADALIMUMAB-AQVH GOLIMUMAB CERTOLIZUMAB PEGOL ETANERCEPT INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

#	Side effect	Count
0	DRUG INEFFECTIVE	116495
1	OFF LABEL USE	78162
2	ARTHRALGIA	66454
3	INJECTION SITE PAIN	60603
4	PAIN	60522
5	RHEUMATOID ARTHRITIS	60409
6	FATIGUE	47609
7	CONDITION AGGRAVATED	45178
8	INJECTION SITE ERYTHEMA	42342
9	HEADACHE	37827

See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	INJECTION SITE RECALL REACTION	486	0.9662
1	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE	6062	0.8885
2	RHEUMATOID FACTOR POSITIVE	4775	0.8542
3	ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY	551	0.8425
4	SWOLLEN JOINT COUNT INCREASED	2442	0.8275
5	RED BLOOD CELL SEDIMENTATION RATE ABNORMAL	1862	0.8185
6	RHEUMATIC FEVER	3370	0.8136
7	PEMPHIGUS	9378	0.7852
8	LUPUS VULGARIS	845	0.7846
9	C-REACTIVE PROTEIN ABNORMAL	4720	0.7655

See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]